Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab.

Emily S Lebow,Annemarie Shepherd,Jordan E Eichholz,Michael Offin,Daphna Y Gelblum,Abraham J Wu,Charles B Simone,Adam J Schoenfeld,David R Jones,Andreas Rimner,Jamie E Chaft,Nadeem Riaz,Daniel R Gomez,Narek Shaverdian

JAMA network open（2023）

引用 1|浏览33

暂无评分

摘要

In this cohort study, TMB-high status was associated with improved local-regional control and PFS after definitive chemoradiation and adjuvant durvalumab. TMB status may facilitate risk-adaptive radiation strategies in unresectable locally advanced NSCLC.

查看译文

关键词

non–small cell lung cancer,tumor mutational burden,lung cancer,durvalumab,chemoradiation,progression-free,local-regional

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要